Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Margherita RiminiMara PersanoToshifumi TadaGoki SudaShigeo ShimoseMasatoshi KudoJaekyung CheonFabian FinkelmeierHo Yeong LimJosé PresaGianluca MasiChanghoon YooSara LonardiFabio PiscagliaTakashi KumadaNaoya SakamotoHideki IwamotoTomoko AokiHong Jae ChonVera HimmelsbachTiziana PressianiMargarida MontesCaterina VivaldiCaterina SoldàAtsushi HiraokaTakuya ShoTakashi NiizekiNaoshi NishidaChristoph SteupMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaTakashi NishimuraTakeshi HatanakaSatoru KakizakiNoritomo ShimadaKazuhito KawataFujimasa TadaHideko OhamaKazuhiro NousoAsahiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiHisashi KosakaAtsushi NaganumaYohei KoizumiShinichiro NakamuraMasaki KaiboriHiroko IijimaYoichi HiasaValentina BurgioLorenza RimassaMario ScartozziStefano CascinuAndrea Casadei-GardiniPublished in: Targeted oncology (2023)
Adherence to the IMbrave150 trial inclusion criteria favorably impacts the prognosis of patients receiving atezolizumab plus bevacizumab. Among patients who did not meet the IMbrave150 inclusion criteria, those with ALBI grade 1 could benefit from the treatment.